Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital
CAR-T cell therapy is a promising treatment for acute leukemia and lymphoma. CAR-T cell therapies take a pioneering role in autologous gene therapy with three EMA-approved products. However, the chance of clinical success remains relatively low as the applicability of CAR-T cell therapy suffers from...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2022.913287/full |
| _version_ | 1811243903170379776 |
|---|---|
| author | Simon Hort Laura Herbst Niklas Bäckel Frederik Erkens Bastian Niessing Maik Frye Niels König Ioannis Papantoniou Ioannis Papantoniou Ioannis Papantoniou Michael Hudecek John J. L. Jacobs Robert H. Schmitt Robert H. Schmitt |
| author_facet | Simon Hort Laura Herbst Niklas Bäckel Frederik Erkens Bastian Niessing Maik Frye Niels König Ioannis Papantoniou Ioannis Papantoniou Ioannis Papantoniou Michael Hudecek John J. L. Jacobs Robert H. Schmitt Robert H. Schmitt |
| author_sort | Simon Hort |
| collection | DOAJ |
| description | CAR-T cell therapy is a promising treatment for acute leukemia and lymphoma. CAR-T cell therapies take a pioneering role in autologous gene therapy with three EMA-approved products. However, the chance of clinical success remains relatively low as the applicability of CAR-T cell therapy suffers from long, labor-intensive manufacturing and a lack of comprehensive insight into the bioprocess. This leads to high manufacturing costs and limited clinical success, preventing the widespread use of CAR-T cell therapies. New manufacturing approaches are needed to lower costs to improve manufacturing capacity and shorten provision times. Semi-automated devices such as the Miltenyi Prodigy® were developed to reduce hands-on production time. However, these devices are not equipped with the process analytical technology necessary to fully characterize and control the process. An automated AI-driven CAR-T cell manufacturing platform in smart manufacturing hospitals (SMH) is being developed to address these challenges. Automation will increase the cost-effectiveness and robustness of manufacturing. Using Artificial Intelligence (AI) to interpret the data collected on the platform will provide valuable process insights and drive decisions for process optimization. The smart integration of automated CAR-T cell manufacturing platforms into hospitals enables the independent manufacture of autologous CAR-T cell products. In this perspective, we will be discussing current challenges and opportunities of the patient-specific but highly automated, AI-enabled CAR-T cell manufacturing. A first automation concept will be shown, including a system architecture based on current Industry 4.0 approaches for AI integration. |
| first_indexed | 2024-04-12T14:15:30Z |
| format | Article |
| id | doaj.art-9bb8ea8db6534f5982f371b47e1dbc02 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-12T14:15:30Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-9bb8ea8db6534f5982f371b47e1dbc022022-12-22T03:29:43ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2022-06-01910.3389/fmed.2022.913287913287Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing HospitalSimon Hort0Laura Herbst1Niklas Bäckel2Frederik Erkens3Bastian Niessing4Maik Frye5Niels König6Ioannis Papantoniou7Ioannis Papantoniou8Ioannis Papantoniou9Michael Hudecek10John J. L. Jacobs11Robert H. Schmitt12Robert H. Schmitt13Fraunhofer Institute for Production Technology IPT, Aachen, GermanyFraunhofer Institute for Production Technology IPT, Aachen, GermanyFraunhofer Institute for Production Technology IPT, Aachen, GermanyFraunhofer Institute for Production Technology IPT, Aachen, GermanyFraunhofer Institute for Production Technology IPT, Aachen, GermanyFraunhofer Institute for Production Technology IPT, Aachen, GermanyFraunhofer Institute for Production Technology IPT, Aachen, GermanyInstitute of Chemical Engineering Sciences, Foundation for Research and Technology-Greece (FORTH), Patras, GreeceSkeletal Biology and Engineering Research Centre, Department of Development and Regeneration, KU Leuven, Leuven, BelgiumPrometheus the Leuven R&D Translational Division of Skeletal Tissue Engineering, KU Leuven, Leuven, BelgiumLehrstuhl für Zelluläre Immuntherapie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, GermanyORTEC BV, Zoetermeer, NetherlandsFraunhofer Institute for Production Technology IPT, Aachen, GermanyLaboratory for Machine Tools and Production Engineering (WZL) of RWTH Aachen University, Aachen, GermanyCAR-T cell therapy is a promising treatment for acute leukemia and lymphoma. CAR-T cell therapies take a pioneering role in autologous gene therapy with three EMA-approved products. However, the chance of clinical success remains relatively low as the applicability of CAR-T cell therapy suffers from long, labor-intensive manufacturing and a lack of comprehensive insight into the bioprocess. This leads to high manufacturing costs and limited clinical success, preventing the widespread use of CAR-T cell therapies. New manufacturing approaches are needed to lower costs to improve manufacturing capacity and shorten provision times. Semi-automated devices such as the Miltenyi Prodigy® were developed to reduce hands-on production time. However, these devices are not equipped with the process analytical technology necessary to fully characterize and control the process. An automated AI-driven CAR-T cell manufacturing platform in smart manufacturing hospitals (SMH) is being developed to address these challenges. Automation will increase the cost-effectiveness and robustness of manufacturing. Using Artificial Intelligence (AI) to interpret the data collected on the platform will provide valuable process insights and drive decisions for process optimization. The smart integration of automated CAR-T cell manufacturing platforms into hospitals enables the independent manufacture of autologous CAR-T cell products. In this perspective, we will be discussing current challenges and opportunities of the patient-specific but highly automated, AI-enabled CAR-T cell manufacturing. A first automation concept will be shown, including a system architecture based on current Industry 4.0 approaches for AI integration.https://www.frontiersin.org/articles/10.3389/fmed.2022.913287/fullATMPCAR-T cellartificial intelligenceautomationautologousmanufacturing |
| spellingShingle | Simon Hort Laura Herbst Niklas Bäckel Frederik Erkens Bastian Niessing Maik Frye Niels König Ioannis Papantoniou Ioannis Papantoniou Ioannis Papantoniou Michael Hudecek John J. L. Jacobs Robert H. Schmitt Robert H. Schmitt Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital Frontiers in Medicine ATMP CAR-T cell artificial intelligence automation autologous manufacturing |
| title | Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital |
| title_full | Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital |
| title_fullStr | Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital |
| title_full_unstemmed | Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital |
| title_short | Toward Rapid, Widely Available Autologous CAR-T Cell Therapy – Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital |
| title_sort | toward rapid widely available autologous car t cell therapy artificial intelligence and automation enabling the smart manufacturing hospital |
| topic | ATMP CAR-T cell artificial intelligence automation autologous manufacturing |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2022.913287/full |
| work_keys_str_mv | AT simonhort towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital AT lauraherbst towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital AT niklasbackel towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital AT frederikerkens towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital AT bastianniessing towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital AT maikfrye towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital AT nielskonig towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital AT ioannispapantoniou towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital AT ioannispapantoniou towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital AT ioannispapantoniou towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital AT michaelhudecek towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital AT johnjljacobs towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital AT roberthschmitt towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital AT roberthschmitt towardrapidwidelyavailableautologouscartcelltherapyartificialintelligenceandautomationenablingthesmartmanufacturinghospital |